Calidi Biotherapeutics Inc. Highlights 2025 Pipeline Progress and Strategic Focus in Shareholder Letter

Calidi Biotherapeutics Inc. (NYSE American: CLDI) has shared a shareholder letter from CEO Eric Poma, PhD, detailing the company's significant progress in 2025, including operational streamlining and advancements in its RedTail platform. This platform, a systemically delivered virotherapy, targets metastatic cancers and delivers genetic payloads, with preclinical data presented at AACR and ASCO highlighting its tumor selectivity and immune modulation potential. The company is advancing its lead candidate, CLD-401, towards IND-enabling studies, expecting to file by the end of 2026, and has opened an IND for CLD-201, with Phase I trials anticipated by year-end. With $10.6 million in cash and a reduced burn rate at the end of Q1, Calidi is focused on rapidly advancing its pipeline while enhancing shareholder value.